Pureos Bioventures
Venture capitalPfäffikon · Seed–Series C · 9 people tracked
Find your way into Pureos Bioventures
1,492 people in our graph share verified history with the Pureos Bioventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Pureos Bioventures provides venture capital to private companies developing innovative therapeutics for severe diseases and conditions. The firm emphasizes the next generation of biological drugs and novel drug formats, aiming to improve patients' lives by advancing new treatments. It backs strong founding teams with development programs that make a meaningful difference for patients, and its portfolio spans oncology, fibrosis, immune-mediated inflammatory diseases, neurological disorders, ophthalmology, cardiovascular disease, vaccines and rare diseases. The team combines career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors and experienced drug developers.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from public directories
Founder mafia
4 people who came through Pureos Bioventures went on to found or lead other companies.
What they invest in
from 19 of 27 portfolio companiesBiotech ×16Healthtech ×13Medical Devices ×11AI & Machine Learning ×6Deep Tech ×4Advanced Manufacturing ×1B2B Marketplaces ×1Data & Infrastructure ×1
HQs:Switzerland×4United States×2Denmark×1France×1Netherlands×1Sweden×1
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×32 founders×5
Investments · 27 tracked
founders shown can be your intro pathBy year:2025 · 22024 · 32022 · 52021 · 22020 · 214 dated
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investors3B Future Health FundIndustrifondenNovo HoldingsSound Bioventures
Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy.
BiotechMedical DevicesBasel, CH
Dragan Grabulovski(Co-founder and CEO)inPhilipp Spycher(Co-founder and Chief Scientific Officer)inIsabella Attinger-Toller(Co-founder)in
Co-investorsredalpineSamsung VenturesVI Partnersb2ventureKinled Holding
Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.
BiotechHealthtechMedical DevicesOss, NL
Renato Chirivi(Co-founder (former CSO))in
BoardPaul Peter Tak(Chair of the Board)
Co-investorsBioGeneration VenturesForbionJohnson & Johnson Innovation – JJDCSeventure PartnersBOMCurie Capital+1 more
Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications.
AI & Machine LearningBiotechDeep Tech
Rodrigo Vazquez-LombardiinSai Reddyin
Co-investorsNovo Holdings
Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases.
BiotechMedical DevicesZurich, CH
Co-investorsKurma PartnersYsios CapitalAdjuvant CapitalFresenius Medical Care VenturesVerve Venturesredalpine
.jpeg){kind=logo}
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsAdjuvant CapitalIndustrifondenOrbiMedSanofi VenturesSunstone CapitalEQT Life Sciences+2 more
NovaGo Therapeutics is a biotech company developing antibody-based therapeutics to promote nerve repair and recovery following spinal cord injury.
BiotechMedical DevicesSchlieren, CH
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness.
BiotechHealthtechMedical Devices
Co-investors+ND Capital
Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.
BiotechDeep TechHealthtechParis, FR
Co-investorsAdvent Life SciencesBioqube VenturesBpifranceAdBio partners
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsDroia VenturesKurma PartnersEQT Life SciencesSeroba Life SciencesEurazeoIdinvest Partners+1 more
Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Peter Blume-Jensen(Executive Officer, Director)Kristina Masson(Executive Officer, Director)erick gamelininEric Devroe(Executive Officer)in
BoardMarcin Czernik(Director)Sharon Shacham(Director)
Co-investorsNew Enterprise Associates (NEA)RA Capital
Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.
BiotechHealthtechMedical Devices
Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in
Co-investorsaMoonRA CapitalBpifranceAndera PartnersAngelini VenturesKurma Partners+1 more
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesJeito CapitalLongitude CapitalNovo Holdings+5 more
HealthtechParis
Ronald Buggage(Executive Officer)Thierry Bordet(Executive Officer)Francine Behar Cohen(Executive Officer, Promoter)Patricia Zilliox(Executive Officer, Director, Promoter)
Co-investorsKaristaPontifax Venture Capital
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAltium CapitalAmgen VenturesDroia VenturesFrazier Healthcare Partners+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom Investment+5 more
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Daniel Olive(Founder)
Co-investorsAgent CapitalAndera PartnersKurma PartnersPfizer Venture InvestmentsAlexandriaBpifrance+4 more
Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss.
BiotechHealthtechMedical Devices
Co-investorsPolaris Partners
VICO provides AI-generated forecasts and event risk ratings that track and triangulate analyst views into continuous time series data.
AI & Machine LearningData & InfrastructureFintech
Co-investorsAIN VenturesMultiball CapitalDroia VenturesEQT Life SciencesEurazeoKurma Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ariceum TherapeuticsBaseLaunchCallio TherapeuticsCorlieve TherapeuticsEvidence BioMediarRiver RenalTridek-One
Exits · 2
2 acquisitionsMemo Therapeuticsacq. by ClementiaImcheckacq. by Clementia
Portfolio news
latest coverage across their companies
Hummingbird · daysofobservance.com · Sep 4, 2026
NovaGo Therapeutics · vir.com.vn · Sep 3, 2026
Memo Therapeutics · investing.com · Jul 22, 2026
PulseSight Therapeutics · ophthalmologytimes.com · Jul 18, 2026
Alentis · biopharminternational.com · Jun 29, 2026
Tavo Biotherapeutics · intelligence360.news · Jun 29, 2026
Hummingbird Bioscience · fiercebiotech.com · Dec 19, 2025
Adcytherix · pharmaceutical-technology.com · Oct 17, 2025
Frequently asked questions
- How many investments has Pureos Bioventures made?
- Pureos Bioventures has 27 tracked investments, 2 of which have exited, including 2 dated in the last 24 months.
- What stage does Pureos Bioventures invest at?
- Pureos Bioventures invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Pureos Bioventures focus on?
- Pureos Bioventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Pureos Bioventures located?
- Pureos Bioventures is headquartered in Pfäffikon, CH.
- Who does Pureos Bioventures co-invest with?
- Pureos Bioventures most often shares deals with Kurma Partners, Frazier Life Sciences, RA Capital, among 40 tracked co-investors.
Images
Co-investors · 11
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Andera Partners is an asset management firm specializing in private equity that partners with companies and their management to support sustainable growth. It has backed 377 companies over more than 20 years.
Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.
Adjuvant Capital is a venture capital firm that finances life science technologies addressing high-burden public health challenges, aiming to deliver both social and financial returns.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
HealthCap is a life science venture capital investor and company creator that backs innovative healthcare ideas, people, and companies aiming to impact healthcare and society.
Earlybird Venture Capital is a European venture capital investor that backs early-stage technology founders with capital, strategic support, and access to an international network.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
4BIO Capital is a London-based venture capital firm investing in life sciences, with a focus on advanced therapies that address high unmet medical and social needs.
Firms observed investing alongside Pureos Bioventures, from public investor directories. Shared companies are the overlap with Pureos Bioventures's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.